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Abstract: Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been 
investigated in many trials, in particular, in order to assess its antihypertensive effect in vari-
ous situations and its ability to protect organs susceptible to hypertension. In addition to its 
antihypertensive properties, it has positive metabolic and vascular effects (partly because of 
its sustained action). Several large-scale trials have focused on the effect of telmisartan on 
cardiovascular morbidity and mortality, including comparisons of that with an angiotensin-
converting enzyme inhibitor in subjects at high vascular risk. Telmisartan was used in the largest 
ARB research programme (the Ongoing Telmisartan Alone and in Combination with Ramipril 
Global Endpoint Trial [ONTARGET] and Telmisartan Randomized Assessment Study in ACE 
Intolerant Subjects with Cardiovascular Disease [TRANSCEND] trial).
Keywords: angiotensin II receptor blocker cardiovascular risk, hypertension, blood pressure, 
renin–angiotensin–aldosterone system
Blood pressure and vascular risk management
Hypertension is an extremely common pathology worldwide, and its effects on 
certain organs, such as the heart, the arteries, the kidneys, and the brain or retina, 
are well characterized. Many trials have shown that hypertension is a continuous, 
independent risk factor for cardiovascular (CV) disease. Once a patient has been 
diagnosed with hypertension, the practitioner should assess the cause and effects of 
the hypertension before initiating the pharmaceutical treatment.1 It is also important 
to assess the overall CV risk of the patient with hypertension, which is evaluated on 
the basis of not only blood pressure (BP) readings but also other risk factors such 
as age, gender, dyslipidemia, diabetes mellitus, smoking, and excess abdominal 
weight or obesity. Risk should also be estimated using specific markers, such as 
albuminuria or increased plasma creatinine, left ventricular hypertrophy (LVH), 
and subclinical vascular damage, and preexisting CV, cerebrovascular, and renal 
pathologies are also taken into account.2 Once overall CV risk has been assessed, 
it should be taken into account for planning the treatment strategy, and all of the 
following variables can be adjusted: initiation time; therapeutic class and even 
the specific molecule used; dosage; monotherapy or combination therapy from 
the outset; and prescription of a lipid-lowering drug, an antidiabetic drug, or an 
antiplatelet drug. In all cases, it is essential to advise the patient about diet and 
lifestyle factors.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Patient adherence: monotherapy  
vs combination therapy
Whether first-line treatment for hypertension should be 
based on a single drug or a combination will not be addressed 
here. However, once antihypertensive treatment is indicated, 
everything must be done to ensure that it is as effective as 
possible, meaning that individual BP targets must be met 
and the regimen must be tolerated. The patient’s compliance 
is dependent on both these parameters. If the BP targets 
are reached, especially if they are reached quickly, and if 
the treatment is well tolerated, compliance is more likely. 
Another significant factor is the number of tablets to be taken 
by the patient each day. In 18,806 newly diagnosed patients 
with hypertension older than 35 years, significant positive 
correlation was shown between combination antihypertensive 
therapy and compliance.3 In the same trial, good compli-
ance was associated with a 38% decrease in the risk of CV 
events when compared with poor compliance. These find-
ings indicate that well-tolerated treatments that are effective 
at lowering the BP and preventing CV events are the way 
forward, as are fixed combinations in cases of multiple anti-
hypertensive therapy. However, the optimal drug treatment 
management and education with the aim of reducing CV risk 
comes at a price. A recent trial showed that the most effective 
approaches to improving compliance with antihypertensive 
(and also lipid-lowering) therapy are intensive and multifac-
eted and are therefore likely to be expensive.4
Pharmacology and the effect 
of telmisartan on biological 
parameters and the endothelium
Pharmacology
The renin–angiotensin–aldosterone system (RAAS) is involved 
in most of CV , cerebral, and renal problems. Its activation is an 
adaptive mechanism, but it can become overactive, leading to 
hypertension, heart failure, and impaired glomerular function. 
Angiotensin II-mediated activation of the angiotensin II type 1 
(AT1) receptor has numerous effects, such as   vasoconstriction, 
sodium and water retention, vascular and myocardial fibrosis 
and hypertrophy, and sympathetic nervous system activation5 
(Table 1). RAAS blockade is used for therapeutic reasons 
in various branches of medicine, hence the development 
of aldosterone antagonists, angiotensin-converting enzyme 
(ACE) inhibitors, AT1 receptor blockers (ARBs), and more 
recently a direct renin inhibitor (aliskiren).
On physiological and pathophysiological levels, 
ARBs antagonize angiotensin II more effectively than 
ACE   inhibitors, in particular, by suppressing the effect of 
  angiotensin II produced by alternative enzyme pathways 
such as those based on trypsin, cathepsin, and heart chy-
mase. Furthermore, contrary to ACE inhibitors, ARBs 
do not suppress, and in fact even increase, angiotensin II 
  subtype 2 (AT2) receptor stimulation, thereby inhibiting 
vascular growth and apoptosis and promoting cell differen-
tiation and vasodilatation.
Seven active oral ARBs – losartan, irbesartan, valsartan, 
candesartan, telmisartan, eprosartan, and olmesartan – are 
currently used in clinical practice. Among these ARBs, 
telmisartan has an advantageous kinetic profile with a longer 
half-life, higher lipophilicity, larger distribution volume, and 
negligible renal clearance.6,7 These properties mean that it can 
readily enter the tissue compartments by effectively blocking 
the RAAS (insurmountable angiotensin II inhibition) both 
systemically and locally. Moreover, telmisartan blocks the 
AT1 receptor for longer and has a greater binding affinity than 
other ARBs.6–8 Its affinity for the AT1 receptor is 3,000 times 
higher than its affinity for the AT2 receptor.9 It also dissociates 
from AT1 receptors very slowly, which explains its sustained 
action.8,10 Results of pharmacological trials have led to a rec-
ommended dose of 20–80 mg for hypertension.
Biological effects
Many trials have shown that agents that target the RAAS 
have positive effects on thrombosis, platelet aggregation, and 
Table 1 Biological effects of telmisartan
Angiotensin II type 1 receptors blockage
↓ activation of sympathetic nervous system
↓ endothelin secretion
↑ NO activity
↓ vasoconstriction
↓ vascular and myocardial growth/hypertrophy and fibrosis
↓ apoptosis
Improvement in endothelial function
↓ sodium and water retention
↓ platelet aggregation
Anti-thrombotic effect
↓ systemic inflammation
↓ oxidative stress
Angiotensin II type 2 receptors stimulation
↓ vascular and myocardial growth/hypertrophy and fibrosis
Cell differentiation
vasodilatation
Other mechanisms
Stimulation of PPAR-γ
↑ insulin sensitivity
↓ glucose and triglycerides levels
↑ adiponectin levels
Abbreviations:  NO,  nitric  oxyde;  PPAR-γ,  peroxisome  proliferator-activator 
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inflammation, although these effects vary from one compound 
to another. In a 1-month trial conducted on 36 patients with 
hypertension (16 treated with telmisartan and 20 with the ACE 
inhibitor perindopril), telmisartan had a better anticoagulant and 
rheological effects than perindopril, with decreases in the levels 
of soluble endothelial protein C receptor and fibrinogen.11
Telmisartan has a particularly attractive metabolic pro-
file when compared with other ARBs. It is the strongest 
stimulator of peroxisome proliferator-activated receptor-γ 
(PPAR-γ), an intracellular regulator of lipid and glucose 
metabolism, exerting anti-inflammatory, antioxidative, and 
antiproliferative effects on vascular cells.12,13 This property 
explains its beneficial metabolic effects – which are unique 
among the ARBs – on glucose and triglyceride levels and 
insulin sensitivity.14 In patients with hypertension with 
impaired glucose tolerance, telmisartan improves insulin 
resistance more effectively than losartan.15 It has been 
clearly demonstrated that ACE inhibitors and ARBs lead to 
the development of fewer new cases of type 2 diabetes.16 In 
the Ongoing Telmisartan Alone and in Combination with 
Ramipril Global Endpoint Trial (ONTARGET), telmisar-
tan 80 mg was as effective as ramipril 10 mg in preventing 
new-onset diabetes in patients at high vascular risk.17 This 
is significant when we consider that, in the Heart Outcomes 
Prevention Evaluation (HOPE) trial, there was a relative risk 
reduction of 34% for diabetes in the ramipril group when 
compared with placebo group.18
Recently, a substudy of the Telmisartan versus Ramipril in 
Renal Endothelium Dysfunction (TRENDY) trial, including 
87 patients with type 2 diabetes, showed that telmisartan leads 
to a significant increase in adiponectin (a peptide hormone 
produced in adipose tissue) compared with ramipril.19 This 
is particularly interesting because adiponectin has benefi-
cial effects on atherogenesis, endothelial function, vascular 
remodeling, inflammation, and insulin resistance.20
Telmisartan and endothelial dysfunction
Endothelial dysfunction is now a recognized marker for CV 
risk.1 Many conditions, including hypertension and diabetes, 
are associated with endothelial dysfunction. RAAS blockers 
appear to be a particularly interesting solution to this vascular 
anomaly. A recent trial on patients with hypertension with 
impaired glucose tolerance showed that telmisartan improved 
endothelial function (brachial flow-mediated dilatation) to 
a greater extent than did losartan.15 In patients with type 2 
diabetes, both telmisartan 40–80 mg and ramipril 5–10 mg 
significantly increased nitric oxide (NO) activity in the renal 
endothelium.21 This positive effect on endothelial function 
goes a long way in explaining why telmisartan improves 
vascular prognosis.
Antihypertensive efficacy  
and end-organ protection
Telmisartan: proven efficacy  
against hypertension
Several trials and a meta-analysis have assessed   BP-lowering 
effect of telmisartan.22 In the meta-analysis, the mean 
clinical BP reduction observed in 408 patients with 
grade 1–2 hypertension after 8–12 weeks administration 
of   telmisartan 40–80 mg was −15.5 mmHg for systolic BP 
and −11.3 mmHg for diastolic BP. Naturally, telmisartan 
was not only compared to placebo but, more interestingly, 
also compared to other antihypertensive agents, including 
ACE inhibitors and ARBs. The Preferred Reporting Items 
for   Systematic Reviews and Meta-Analyses (PRISMA) 1 
and 2 trials compared the efficacy of telmisartan 40–80 mg 
with that of ramipril 5–10 mg on 24-hour BP readings.23–25 
BP decreased more sharply with telmisartan 80 mg than with 
ramipril 10 mg (−12.7/−8.8 mmHg vs −7.9/−5.4 mmHg, 
P , 0.0001), especially in subjects with a marked morning 
BP surge.
Telmisartan 80 mg+ hydrochlorothiazide(HCTZ) was 
compared with valsartan 160 mg + HCTZ in an 8-week trial 
of 1,181 patients with hypertension.26 BP decreased more 
sharply in the telmisartan group than in the valsartan group 
(−24.6/−18.2 mmHg vs −22.5/−17.0 mmHg, P , 0.05). The 
antihypertensive effect of telmisartan was greater than not 
only that of valsartan but also that of losartan.27,28 Thus, in a 
trial comparing the antihypertensive efficacy of telmisartan 
40 or 80 mg + HCTZ and losartan 50 mg + HCTZ in 805 
patients with grade 1–2 hypertension, both telmisartan doses 
were more effective than losartan at normalizing BP in the 6 
hours preceding the morning dose.29
Telmisartan has also been shown to be effective against 
hypertension in overweight and obese patients with diabetes. 
In the SMOOTH trial conducted on 840 patients who pre-
sented these comorbidities, telmisartan 80 mg + HCTZ was 
more effective than valsartan 160 mg + HCTZ at lowering 
the 24-hour BP over 10 weeks, and over the last 6 hours of 
the therapeutic window.30 Elderly patients with difficult-  to-
control isolated systolic hypertension have also benefited 
from telmisartan. Thus, the ATHOS trial of 872 subjects 
older than 60 years showed that BP decreased more sharply 
over 24 hours with telmisartan 40–80 mg (+HCTZ 12.5 mg) 
treatment than with amlodipine 5–10 mg (+HCTZ 12.5 mg) 
treatment.31 In this trial, the percentage of patients with Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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  controlled systolic BP was higher in the telmisartan group 
than in the amlodipine group (65.9% vs 58.3%, P = 0.02).
Finally, a recent analysis of 24-hour ambulatory BP data 
from the ONTARGET showed that telmisartan was more 
effective in controlling nocturnal BP than ramipril.32
These positive results with telmisartan are due not only 
to its BP-lowering efficacy but also to its long duration of 
action.
Telmisartan’s efficacy against  
end-organ damage
Renal disease
CV risk factors underlie arterial, myocardial, cerebral/ocular, 
and renal lesions. Among these risk factors, hypertension 
and diabetes are key factors, particularly in the development 
of nephropathy. It is therefore essential not only to prevent 
existing renal lesions from worsening (secondary   prevention), 
but also to prevent the formation of lesions in the first place 
(primary prevention). Recommendations on treating patients 
with hypertension and/or diabetes emphasize the potential ben-
efit of RAAS inhibitors, in particular, when the patients have 
renal failure and/or proteinuria.1,33 Among the RAAS inhibi-
tors, several trials have shown that ARBs merit a special place, 
particularly in patients with type 2 diabetes.34–36 Telmisartan is 
one of the drugs that have proven their worth in this area.
The INNOVATION trial, conducted on 514 hypertensive 
or normotensive subjects with type 2 diabetes and microal-
buminuria but no renal failure, showed that both doses of 
telmisartan 80 mg and 40 mg slowed down the appearance 
of overt nephropathy when compared with placebo (16.7%, 
22.6%, and 49.9%, respectively, after a mean follow-up 
period of 1.3 years).37 This positive effect of telmisartan 
has been observed in patients with hypertension, regardless 
of their BP.
The DETAIL trial of 250 patients with type 2 diabetes and 
incipient nephropathy showed that telmisartan 40–80 mg and 
enalapril 20 mg had similar effects on the progressive loss of 
glomerular filtration function over a 5-year period.38
The AMADEO trial of 860 patients with type 2 diabetes 
with overt nephropathy (morning spot urine protein-to-
creatinine ratio of 700 or more) demonstrated that telm-
isartan 40 mg preserved kidney function more effectively 
than losartan 50 mg.39 In this trial, proteinuria reduced after 
52 months by 29% with telmisartan compared with only 
20% with losartan (P , 0.05) treatment, independently of 
the decrease in BP.
The VIVALDI trial found similar reductions in pro-
teinuria with telmisartan 80 mg and valsartan 160 mg in 
885 patients with hypertension and type 2 diabetes (protei-
nuria $ 900 mg/24 hour and serum creatinine # 3.0 mg/dL) 
over the 52 weeks of the trial.40
The ARAMIS trial of 614 patients, who did not neces-
sarily have diabetes, with isolated systolic hypertension and 
albuminuria . 2.2 mg/L showed that the reduction in urinary 
albumin excretion was greater in the telmisartan 20–80 mg 
group than in the HCTZ 12.5 mg group.41
A recent meta-analysis indicated that the combination 
of an ACE inhibitor and an ARB reduces proteinuria to a 
greater extent than does either drug alone.42 With respect to 
the efficacy of this combination vis-à-vis renal function and 
CV events, one of the aims of the ONTARGET (this trial 
will be explained later in greater detail) was to investigate 
the long-term nephrological outcome in 25,620 subjects 
at high vascular risk, taking telmisartan 80 mg vs ramipril 
10 mg or a combination of these 2 drugs.17 After a follow-up 
period of 56 months, the primary renal end point (a compos-
ite parameter of dialysis, doubling of serum creatinine, and 
death) was similar for both telmisartan (13.4%) and ramipril 
(13.5%), but was superior with the combination therapy 
(14.5%, P = 0.037).43 The estimated glomerular filtration rate 
decreased less with ramipril than with telmisartan (−2.82 vs 
−4.12 mL/min/1.73 m², P , 0.0001) or combination therapy 
(−6.11, P , 0.0001), but urinary albumin excretion increased 
less with telmisartan (25%, P = 0.033) and combination 
therapy (22%, P = 0.0028) than it did with ramipril (32%). 
In light of these results, we can conclude first that renal 
protection is identical with ARBs and ACE inhibitors in 
the high vascular risk population, and second that a serious 
renal event, as well as hypotensive symptoms and syncope, is 
more likely to occur with the combination of ARB and ACE 
inhibitor. This combination should therefore be prescribed 
only to patients with heart failure that is not controlled by 
ACE inhibitors44,45 (it is the only licensed indication).
Left ventricular hypertrophy
Although LVH does not have a direct effect on vascular 
risk, it is important to be aware of the impact of any given 
antihypertensive agents on this pathological process. Some 
trials have shown that telmisartan significantly reduces 
LVH in patients with hypertension. In fact, telmisartan 
induces greater LVH regression than carvedilol, ramipril, 
and HCTZ, despite comparable BP reductions.46–48 In the 
ONTARGET and Telmisartan Randomized Assessment 
Study in ACE Intolerant Subjects with Cardiovascular 
Disease   (TRANSCEND) trial (see design later), the effect 
of telmisartan on LVH (electrocardiogram criteria) was Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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studied in patients at high vascular risk without known heart 
failure.17,49 In TRANSCEND trial, telmisartan 80 mg was 
more effective than placebo in reducing LVH (P = 0.0017, 
Figure 1).50 Moreover, new-onset LVH decreased by 37% 
in the telmisartan group. In the ONTARGET, LVH preva-
lence was slightly lower with telmisartan than with ramipril 
(P = 0.07). It is also important to be aware of this positive 
effect, given that LVH is involved in the development of 
heart failure and arrhythmia.
Arterial wall damage
Angiotensin II plays a key role in the initiation and exacerba-
tion of atherosclerosis, and RAAS inhibitors seem to occupy 
a special place among vascular protective treatments. Several 
vascular parameters are used as CV risk markers, including 
the presence of vascular hypertrophy (increased intima-media 
thickness, IMT) and plaques. Interestingly, it has been shown 
in patients with hypertension that telmisartan significantly 
reduces carotid IMT and carotid wall cross-sectional area 
than does ramipril.48
Arterial wall stiffness, which can be assessed using 
carotid-to-femoral pulse wave velocity (PWV), is another CV 
risk marker. It is responsible for an increase in systolic BP and 
a relative decrease in diastolic BP. Reduced arterial stiffness 
on treatment is associated with decreases in morbidity and 
mortality, independently of BP reduction. In TRANSCEND 
trial, the patients taking telmisartan 80 mg tended to have a 
lower PWV (difference of 0.5 m/s) than those taking placebo 
after 2 years of treatment (Roland Asmar, pers comm).
Using telmisartan to prevent  
CV events
Cv prevention
The beneficial role of RAAS inhibition in the secondary 
prevention of CV and renal diseases, and in patients with 
diabetes at high CV risk, has been clearly demonstrated. 
However, what is the best therapeutic strategy in this type 
of patient: ACE inhibitors, ARBs, or a combination of 
both? The HOPE trial compared the effect of ramipril 
10 mg with placebo for a mean follow-up period of 5 years 
in 9,297 patients at high CV risk who had evidence of 
vascular disease or diabetes plus another CV risk factor.18 
In this trial, a primary outcome (myocardial infarction, 
stroke, or death from CV causes) was reached less often 
in patients receiving ramipril (−22%, P , 0.001). The 
recent ONTARGET included 25,620 patients (mean age, 
66.4 years; 73% men and 38% patients with diabetes) who 
were at high risk for vascular events.17 On inclusion, 85% 
of patients had a CV pathology, 49% had already experi-
enced myocardial infarction, but none had presented heart 
failure, 21% were had a stroke, and 69% had hypertension. 
These patients were being well managed (62% were taking 
Figure 1 Beneficial effects of telmisartan compared with placebo at the end of the TRANSCEND study: blood pressure (difference between both groups: −2.6/−1.1 mmHg),49 
cardiovascular events (13.0% vs 14.8%, P = 0.048),49 and electric left ventricular hypertrophy (9.9% vs 12.8%, P = 0.0017).50
Abbreviations: Cv, cardiovascular; DBP, diastolic blood pressure; LvH, left ventricular hypertrophy; MI, myocardial infarction; P, placebo; SBP, systolic blood pressure; 
T, telmisartan.
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a statin and 76% were   taking aspirin). The subjects were 
randomized to receive either telmisartan up to the 80 mg 
or ramipril up to 10 mg per day, or combination therapy. 
The aim of this trial was 2-fold: (1) to demonstrate that 
telmisartan was more effective against the incidence of 
CV events (primary composite outcome: death from CV 
causes, myocardial infarction, stroke, or hospitalization 
for heart failure) and tolerated better than ramipril; and (2) 
to determine whether the combination of telmisartan and 
ramipril was more effective than monotherapy with ramipril 
against the incidence of CV events. The main results of the 
ONTARGET showed that, after a mean follow-up period of 
56 months, the overall incidence of CV events was identi-
cal with telmisartan alone (16.7%), with ramipril alone 
(16.5%), and with the combination of telmisartan and 
ramipril (16.3%). In this trial, the patients in the telmisartan 
group and the combination-therapy group had slightly lower 
BP levels throughout the trial period (mean reductions of 
0.9/0.6 mmHg and 2.4/1/4 mmHg, respectively) than the 
patients in the ramipril group. This is the first trial to show 
that an ARB, telmisartan, is as effective as an ACE inhibitor, 
ramipril, in terms of reducing the risk of all types of CV 
complications occurring in patients at high vascular risk. 
Interestingly, the same trial showed that the main benefit 
of reducing clinical systolic BP to below 130 mmHg was 
the reduction in the incidence of stroke, but the incidence 
of myocardial infarction was unaffected.51
Although ACE inhibitors are indicated in many clinical 
situations, around 20% of patients cannot tolerate them due to 
coughing, hypotension, and impaired renal function. As ACE 
inhibitor-intolerant patients at high vascular risk could not 
be included in the ONTARGET, a separate trial was created 
for them, namely the TRANSCEND trial.49 A total of 5,926 
patients were included in this trial, and the main result showed 
that, after a median follow-up period of 56 months with telm-
isartan 80 mg and placebo, there was a similar incidence of 
CV events (15.7% vs 17.0%). However, in the TRANSCEND 
trial, telmisartan significantly reduced the risk of the second-
ary composite outcome (CV death, myocardial infarction, or 
stroke, ie, the HOPE trial end point) (P = 0.048, Figure 1).
Atrial fibrillation
Atrial fibrillation is associated with increased cardiac 
and vascular risks, particularly stroke. A meta-analysis 
by Healey et al demonstrates that ACE inhibitors and 
ARBs reduce the relative risk of atrial fibrillation by 38% 
(P = 0.0002), with both classes inducing a similar reduction.52 
This positive effect of RAAS inhibitors is seen, in particular, 
in patients with heart failure (−44%). In the ONTARGET, 
which was conducted on patients without known heart failure, 
both drugs (telmisartan and ramipril) had similar effects on 
new-onset atrial fibrillation.17
Cerebrovascular prevention
As mentioned earlier, both ACE inhibitors and ARBs have 
a positive effect at the vascular level. But what about the 
secondary prevention of stroke? The PROGRESS trial of 
6,105 patients showed that a combination of perindopril 
and indapamide reduces the risk of recurrent stroke by 28% 
compared with placebo after a 4-year follow-up period.53 The 
PROFESS trial compared telmisartan 80 mg with placebo 
over 2.5 years in 20,332 patients who had recently experi-
enced an ischemic stroke.54 Stroke recurrence (the primary 
outcome) was similar in both groups (P = 0.23), and the 
same was true for all major CV events. We should however 
remember that, in this trial, 37% of patients in the placebo 
group received an ACE inhibitor, 47% received a statin, and 
100% received aspirin.
Safety and tolerance
Besides efficacy, safety and tolerance are also the essential 
properties of a drug, especially when it is used in the long 
term, as is the case with antihypertensive medications. Several 
trials have shown that ARBs are well tolerated and are prob-
ably even the best-tolerated class of antihypertensive drugs.55 
Several trials have shown that telmisartan is well tolerated, 
in particular, compared with placebo and an ACE inhibitor.
The PRISMA trial showed that the tolerance of both 
ramipril and telmisartan was good, although coughing was 
reported less frequently with the ARB than with the ACE 
inhibitor.24 In the ONTARGET, patients discontinued telm-
isartan less often than ramipril (21.0% vs 23.7%, P = 0.02).17 
Similarly, fewer patients had experienced coughing (1.1% vs 
4.2%, P , 0.001) or angioedema (0.1% vs 0.3%, P = 0.01) on 
treatment with telmisartan. However, although the incidence 
of syncope did not increase, the rate of hypotensive symptoms 
with telmisartan (2.6% vs 1.7%, P , 0.001) was higher. 
An important fact to note is that there were as many renal 
events with telmisartan (10.6%) as with ramipril (10.2%), 
and in particular, a similar number of patients presented with 
doubled creatinine levels. Likewise, the number of patients 
whose potassium levels increased by more than 5.5 mmol/L 
was similar in both monotherapy groups, but higher with the 
combination-therapy groups.
The tolerance of telmisartan was also compared 
with that of amlodipine. In subjects older than 60 years, Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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  telmisartan + HCTZ was better tolerated than the calcium 
channel blocker + HCTZ.31
The consequences of good tolerance of telmisartan are 
essentially improved safety of use and compliance.
In the ONTARGET, a combination of telmisartan 
and ramipril induced more side effects and laboratory 
abnormalities than ramipril alone.17 In particular, syncope 
was more common (0.3% vs 0.2%, P = 0.03), as were 
episodes of renal failure (1.1% vs 0.7%, P , 0.001) and 
hyperkalemia.
Conclusion: telmisartan’s place  
in the therapeutic arsenal
The modern approach to treating CV diseases should take 
account not only of individual CV risk factors but also of 
the patient’s overall CV risk. Furthermore, it is essential to 
have access to drugs that have been proven effective for both 
primary and secondary preventions. This is why telmisartan 
warrants a special place in the therapeutic arsenal. It is effec-
tive in reducing BP, it has a favorable metabolic profile, it 
has been proven effective in patients at high vascular risk, 
and it is well tolerated. These data, mostly derived from 
the ONTARGET and TRANSCEND trial, were taken into 
account when the European Society of Hypertension recently 
reappraised its guidelines on hypertension management.33 
Finally, in 2010, telmisartan is indicated for essential 
hypertension in adults and for the prevention of CV disease 
in patients with (1) manifest atherothrombotic CV disease 
(a history of coronary heart disease, stroke, or peripheral 
  arterial disease) or (2) type 2 diabetes mellitus with docu-
mented target-organ damage.
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